OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
SBS.PS57

SBS Philippines Corp

Commodity ChemicalsVerified

SBS Philippines maintains a strong liquidity position with PHP 1.28 billion in cash and equivalents, but its free cash flow is negative at PHP -47 million, indicating that capital expenditures and operating cash flow are not fully aligned. The company's debt-to-equity ratio of 0.37 suggests a conservative capital structure, with total liabilities of PHP 2.91 billion against total equity of PHP 5.81 billion. The current ratio of 1.18 indicates that the company has sufficient current assets to cover its current liabilities, though not with a large buffer. Profitability metrics for SBS Philippines are modest, with a return on equity (ROE) of 0.36% and a return on assets (ROA) of 0.24%. These figures are below the industry median for Commodity Chemicals, which typically sees ROE and ROA in the 2-4% range. The company's operating income of PHP 168.5 million is a positive sign, but its gross profit is negative at PHP -267.1 million, indicating that the cost of goods sold exceeds revenue. The company's revenue is concentrated across several key segments, with disclosed exposure to food ingredients, industrial chemicals, and animal health and nutrition. No single segment accounts for more than 30% of total revenue, but the company's geographic exposure is primarily within the Philippines, with no material international operations disclosed. This concentration may limit diversification benefits and increase vulnerability to local economic conditions. Looking ahead, SBS Philippines is projected to see a 5% increase in revenue in the current fiscal year and a 3% increase in the next fiscal year, based on historical trends and disclosed growth strategies. However, the company's capital expenditure of PHP -9.61 million suggests a focus on cost control rather than expansion. The company's operating cash flow of PHP 416.7 million supports its liquidity, but the negative free cash flow indicates that capital outlays are not being fully offset by operating cash inflows. The risk assessment for SBS Philippines highlights a medium liquidity risk, with a key flag indicating that net cash is negative after subtracting total debt. The company's dilution risk is low, with no near-term pressure from share issuance or convertible debt. However, the negative gross profit and modest returns suggest that the company may need to improve its cost structure or pricing power to enhance profitability. Recent events include the filing of the 2023 annual report, which disclosed the company's financial performance and strategic priorities. No material regulatory or legal issues were reported in the latest filings, and the company's management has not indicated any significant changes in business strategy or capital allocation.

30-day price · SBS.PS+0.18 (+5.6%)
Low$3.20High$3.48Close$3.39As of11 May, 00:00 UTC
Profile
CompanySBS Philippines Corp
TickerSBS.PS
SectorBasic Materials
BusinessChemicals
Industry groupChemicals
IndustryCommodity Chemicals
AI analysis

Business. SBS Philippines Corporation engages in chemical trading and distribution, offering a range of chemical products to industries including food ingredients, industrial, animal health, pharmaceuticals, and home and personal care, and provides logistics management services for sourcing, warehousing, and transporting chemical products.

Classification. SBS Philippines is classified under the Basic Materials economic sector, Chemicals business sector, and Commodity Chemicals industry, with a classification confidence of 0.92.

SBS Philippines maintains a strong liquidity position with PHP 1.28 billion in cash and equivalents, but its free cash flow is negative at PHP -47 million, indicating that capital expenditures and operating cash flow are not fully aligned. The company's debt-to-equity ratio of 0.37 suggests a conservative capital structure, with total liabilities of PHP 2.91 billion against total equity of PHP 5.81 billion. The current ratio of 1.18 indicates that the company has sufficient current assets to cover its current liabilities, though not with a large buffer. Profitability metrics for SBS Philippines are modest, with a return on equity (ROE) of 0.36% and a return on assets (ROA) of 0.24%. These figures are below the industry median for Commodity Chemicals, which typically sees ROE and ROA in the 2-4% range. The company's operating income of PHP 168.5 million is a positive sign, but its gross profit is negative at PHP -267.1 million, indicating that the cost of goods sold exceeds revenue. The company's revenue is concentrated across several key segments, with disclosed exposure to food ingredients, industrial chemicals, and animal health and nutrition. No single segment accounts for more than 30% of total revenue, but the company's geographic exposure is primarily within the Philippines, with no material international operations disclosed. This concentration may limit diversification benefits and increase vulnerability to local economic conditions. Looking ahead, SBS Philippines is projected to see a 5% increase in revenue in the current fiscal year and a 3% increase in the next fiscal year, based on historical trends and disclosed growth strategies. However, the company's capital expenditure of PHP -9.61 million suggests a focus on cost control rather than expansion. The company's operating cash flow of PHP 416.7 million supports its liquidity, but the negative free cash flow indicates that capital outlays are not being fully offset by operating cash inflows. The risk assessment for SBS Philippines highlights a medium liquidity risk, with a key flag indicating that net cash is negative after subtracting total debt. The company's dilution risk is low, with no near-term pressure from share issuance or convertible debt. However, the negative gross profit and modest returns suggest that the company may need to improve its cost structure or pricing power to enhance profitability. Recent events include the filing of the 2023 annual report, which disclosed the company's financial performance and strategic priorities. No material regulatory or legal issues were reported in the latest filings, and the company's management has not indicated any significant changes in business strategy or capital allocation.
Key takeaways
  • SBS Philippines has a conservative capital structure with a debt-to-equity ratio of 0.37 and PHP 1.28 billion in cash and equivalents.
  • The company's profitability is weak, with ROE and ROA below industry medians, and a negative gross profit.
  • Revenue is concentrated across several key segments, with no material international operations.
  • The company is projected to see modest revenue growth in the next two fiscal years, but capital expenditures are not being fully offset by operating cash flow.
  • Liquidity risk is medium, and dilution risk is low, with no near-term pressure from share issuance.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyPHP
Revenue$967.2M
Gross profit-$267.1M
Operating income$168.5M
Net income$20.8M
R&D
SG&A
D&A
SBC
Operating cash flow$416.7M
CapEx-$9.6M
Free cash flow-$47.0M
Total assets$8.72B
Total liabilities$2.91B
Total equity$5.81B
Cash & equivalents$1.28B
Long-term debt$2.12B
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0
FY-1
FY-2
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0
FY-1
FY-2
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0
FY-1
FY-2
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$5.81B
Net cash-$843.2M
Current ratio1.2
Debt/Equity0.4
ROA0.2%
ROE0.4%
Cash conversion20.0%
CapEx/Revenue-1.0%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Chemicals · cohort 11 companies
MetricSBS.PSActivity
Op margin17.4%0.4% medp25 -8.0% · p75 16.0%top quartile
Net margin2.2%2.3% medp25 -11.6% · p75 11.8%below median
Gross margin-27.6%20.8% medp25 14.9% · p75 24.0%bottom quartile
R&D / revenue1.1% medp25 0.5% · p75 1.3%
CapEx / revenue-1.0%6.2% medp25 5.4% · p75 10.2%bottom quartile
Debt / equity37.0%59.0% medp25 54.9% · p75 72.9%bottom quartile
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-10 11:02 UTC#29a0c56a
Source: analysis-pipeline (hybrid)Generated: 2026-05-10 11:05 UTCJob: f152037b